ATE323084T1 - Für die behandlung von alzheimer krankheit geeignete makrocyclen - Google Patents
Für die behandlung von alzheimer krankheit geeignete makrocyclenInfo
- Publication number
- ATE323084T1 ATE323084T1 AT02752056T AT02752056T ATE323084T1 AT E323084 T1 ATE323084 T1 AT E323084T1 AT 02752056 T AT02752056 T AT 02752056T AT 02752056 T AT02752056 T AT 02752056T AT E323084 T1 ATE323084 T1 AT E323084T1
- Authority
- AT
- Austria
- Prior art keywords
- disease
- treatment
- alzheimer
- macrocycles
- useful
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 3
- 150000002678 macrocyclic compounds Chemical class 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 abstract 1
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000008021 deposition Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
- C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29754601P | 2001-06-12 | 2001-06-12 | |
| US33308301P | 2001-11-19 | 2001-11-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE323084T1 true ATE323084T1 (de) | 2006-04-15 |
Family
ID=26970209
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02752056T ATE323084T1 (de) | 2001-06-12 | 2002-06-12 | Für die behandlung von alzheimer krankheit geeignete makrocyclen |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US6969709B2 (enExample) |
| EP (1) | EP1404671B1 (enExample) |
| JP (1) | JP2004534064A (enExample) |
| AT (1) | ATE323084T1 (enExample) |
| BR (1) | BR0210392A (enExample) |
| CA (1) | CA2450202A1 (enExample) |
| DE (1) | DE60210614T2 (enExample) |
| ES (1) | ES2261699T3 (enExample) |
| MX (1) | MXPA03011466A (enExample) |
| WO (1) | WO2002100856A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2469622A1 (en) * | 2001-12-06 | 2003-06-19 | Elan Pharmaceuticals, Inc. | Substituted hydroxyethylamines |
| EP1583750B1 (en) | 2003-01-07 | 2013-02-27 | Merck Sharp & Dohme Corp. | Macrocyclic beta-secretase inhibitors for treatment of Alzheimer's disease |
| US7521481B2 (en) | 2003-02-27 | 2009-04-21 | Mclaurin Joanne | Methods of preventing, treating and diagnosing disorders of protein aggregation |
| ATE457995T1 (de) | 2003-06-18 | 2010-03-15 | Tranzyme Pharma Inc | Makrozyklische motilin rezeptorantagonisten |
| GB0325830D0 (en) * | 2003-11-05 | 2003-12-10 | Novartis Ag | Organic compounds |
| US7652003B2 (en) * | 2004-07-28 | 2010-01-26 | Schering-Plough Corporation | Macrocyclic β-secretase inhibitors |
| GB0500683D0 (en) | 2005-01-13 | 2005-02-23 | Novartis Ag | Organic compounds |
| CA2593268A1 (en) * | 2005-01-13 | 2006-07-20 | Novartis Ag | Macrocyclic compounds useful as bace inhibitors |
| AU2006235344B2 (en) | 2005-04-08 | 2012-07-26 | Comentis, Inc. | Compounds which inhibit beta-secretase activity and methods of use thereof |
| US7338974B2 (en) | 2005-08-12 | 2008-03-04 | Bristol-Myers Squibb Company | Macrocyclic diaminopropanes as beta-secretase inhibitors |
| GB0526614D0 (en) * | 2005-12-30 | 2006-02-08 | Novartis Ag | Organic compounds |
| CN101484431A (zh) * | 2006-07-20 | 2009-07-15 | 诺瓦提斯公司 | 大环内酰胺 |
| RU2009105762A (ru) * | 2006-07-20 | 2010-08-27 | Новартис АГ (CH) | Макроциклические соединения, применимые в качестве ингибиторов васе |
| US7678784B2 (en) | 2006-11-20 | 2010-03-16 | Bristol-Myers Squibb Company | Oxime-containing macrocyclic acyl guanidines as β-secretase inhibitors |
| US7772221B2 (en) | 2007-02-09 | 2010-08-10 | Bristol-Meyers Squibb Company | Diaminopropane derived macrocycles as inhibitors of β amyloid production |
| US20100063013A1 (en) * | 2007-03-26 | 2010-03-11 | Renata Oballa | Cathepsin cysteine protease inhibitors |
| US7732434B2 (en) | 2007-04-20 | 2010-06-08 | Bristol-Myers Squibb Company | Macrocyclic acyl guanidines as beta-secretase inhibitors |
| WO2014144346A1 (en) * | 2013-03-15 | 2014-09-18 | The Board Of Regents Of The University Of Texas System | Use of inhibitors of mtor to improve vascular functions in apoe4 carriers |
| DK3089737T3 (da) | 2013-12-31 | 2021-12-13 | Rapamycin Holdings Llc | Orale rapamycin-nanopartikelpræparater og anvendelse. |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPM982594A0 (en) * | 1994-12-02 | 1995-01-05 | University Of Queensland, The | HIV protease inhibitors |
| EP1192177A1 (en) * | 1999-06-15 | 2002-04-03 | Elan Pharmaceuticals, Inc. | Statine-derived tetrapeptide inhibitors of beta-secretase |
-
2002
- 2002-06-12 AT AT02752056T patent/ATE323084T1/de not_active IP Right Cessation
- 2002-06-12 CA CA002450202A patent/CA2450202A1/en not_active Abandoned
- 2002-06-12 WO PCT/US2002/019076 patent/WO2002100856A1/en not_active Ceased
- 2002-06-12 MX MXPA03011466A patent/MXPA03011466A/es active IP Right Grant
- 2002-06-12 EP EP02752056A patent/EP1404671B1/en not_active Expired - Lifetime
- 2002-06-12 JP JP2003503623A patent/JP2004534064A/ja active Pending
- 2002-06-12 DE DE60210614T patent/DE60210614T2/de not_active Expired - Fee Related
- 2002-06-12 US US10/171,182 patent/US6969709B2/en not_active Expired - Fee Related
- 2002-06-12 BR BR0210392-3A patent/BR0210392A/pt not_active IP Right Cessation
- 2002-06-12 ES ES02752056T patent/ES2261699T3/es not_active Expired - Lifetime
-
2005
- 2005-09-02 US US11/218,879 patent/US7442691B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US7442691B2 (en) | 2008-10-28 |
| JP2004534064A (ja) | 2004-11-11 |
| CA2450202A1 (en) | 2002-12-19 |
| EP1404671B1 (en) | 2006-04-12 |
| US6969709B2 (en) | 2005-11-29 |
| WO2002100856A1 (en) | 2002-12-19 |
| US20030236199A1 (en) | 2003-12-25 |
| EP1404671A1 (en) | 2004-04-07 |
| DE60210614D1 (de) | 2006-05-24 |
| MXPA03011466A (es) | 2004-07-01 |
| DE60210614T2 (de) | 2007-03-01 |
| BR0210392A (pt) | 2004-10-13 |
| US20060040910A1 (en) | 2006-02-23 |
| ES2261699T3 (es) | 2006-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200512195A (en) | Benzamide 2-hydroxy-3-diaminoalkanes | |
| MXPA04000328A (es) | Derivados de alfa-hidroxiamida estatina para tratamiento de enfermedad de alzheimer. | |
| DE60210614D1 (de) | Für die behandlung von alzheimer krankheit geeignete makrocyclen | |
| MXPA04002785A (es) | Aminas sustituidas para tratamiento de enfermedad de alzheimer. | |
| TW200505418A (en) | Phenacyl 2-hydroxy-3-diaminoalkanes | |
| MXPA04006575A (es) | Amino carboxamidas sustituidas para el tratamiento de la enfermedad de alzheimer. | |
| MXPA04000338A (es) | Diamindioles para tratamiento de enfermedad de alzheimer. | |
| MXPA04003245A (es) | Hidroxipropilaminas. | |
| AP2004002952A0 (en) | N-(3-amino-2-hydroxy-propyl) substituted alkylamide compounds. | |
| TW200505828A (en) | Substituted ureas and carbamates useful in the treatment of alzheimer's disease | |
| WO2004022523A3 (en) | 1, 3-diamino-2-hydroxypropane prodrug derivatives | |
| MXPA03011521A (es) | Aminadioles para tratamiento de enfermedad de alzheimer. | |
| MXPA05002420A (es) | Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos. | |
| ATE396174T1 (de) | Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten | |
| EP1689713A4 (en) | BENZYL ETHER AND BENZYLAMINE COMPOUNDS AS INHIBITORS OF BETA-SECRETASE FOR THE TREATMENT OF ALZHEIMER DISEASE | |
| ATE326964T1 (de) | Aminosäurederivate zur behandlung der alzheimer- krankheit | |
| MXPA03011502A (es) | Aminoalcoholes sustituidos utiles en tratamiento de enfermedad de alzheimer. | |
| MXPA04000337A (es) | Amindioles para tratamiento de enfermedad de alzheimer. | |
| BR0314180A (pt) | Aminoéteres substituìdos para o tratamento da doença de alzheimer | |
| WO2004029019A3 (en) | Compounds for the treatment of alzheimer’s disease | |
| DE60219680D1 (de) | Amin-1,2- und -1,3-diolverbindungen und deren verwendung zur behandlung von alzheimer-krankheit | |
| ATE323489T1 (de) | Verwendung von bicyklischen verbindungen für die behandlung von alzheimer | |
| WO2005042472A3 (en) | Hydroxypropyl amides for the treatment of alzheimer’s disease | |
| ECSP044940A (es) | N-(3-amino-2-hidroxil-propil) compuestos substitutos de alquilamida | |
| EA200500382A1 (ru) | Соединения тиазола для лечения нейродегенеративных расстройств |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |